EPISODE · May 8, 2025 · 16 MIN
Munich based Tubulis is working on ADCs that it believes are more durable, potent, and homogenous than others on the market currently - it has signed partnerships with Gilead and Bristol
from BiotechTV - News · host BiotechTV
Co-Founder and CEO Dominik Schumacher describes what he thinks can be improved on from the current generation of antibody-drug conjugates, and the science behind how Tubilis is designing its ADCs differently. He highlights the company's clinical Napi2b and 5T4 programs.
Embed this episode
Ready to play
Munich based Tubulis is working on ADCs that it believes are more durable, potent, and homogenous than others on the market currently - it has signed partnerships with Gilead and Bristol
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.